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Abstract
Objectives: To test for structural and functional contribution of mitochondrial
dysfunction to neurodegeneration in multiple sclerosis (MS). A visual pathway
model void of MS lesions was chosen in order to exclude neurodegeneration
secondary to lesion related axonotmesis. Methods: A single-centre cohort study
(230 MS patients, 63 controls). Spectral domain optical coherence tomography
of the retina, 3T magnetic resonance imaging of the brain, spectrophotometric
assessment of serum lactate levels. Postmortem immunohistochemistry. Results:
The visual pathway was void of MS lesions in 31 patients and 31 age-matched
controls. Serum lactate was higher in MS compared to controls (P = 0.029).
High serum lactate was structurally related to atrophy of the retinal nerve ﬁber
layer at the optic disc (P = 0.041), macula (P = 0.025), and the macular gan-
glion cell complex (P = 0.041). High serum lactate was functionally related to
poor color vision (P<0.01), Expanded Disability Status Scale score (R = 0.37,
P = 0.041), Guy’s Neurological disability score (R = 0.38, P = 0.037), MS
walking scale (R = 0.50, P = 0.009), upper limb motor function (R = 0.53,
P = 0.002). Immunohistochemistry demonstrated increased astrocytic expression
of a key lactate generating enzyme in MS lesions as well as profound vascular
expression of monocarboxylate transporter-1, which is involved in lactate trans-
port. Interpretation: This study provides structural, functional, and transla-
tional evidence for visual pathway neurodegeneration in MS related to
mitochondrial dysfunction.
Introduction
Understanding mechanisms driving progression of
neurodegeneration in multiple sclerosis (MS) is relevant
for developing focused neuroprotective treatment strate-
gies.
1 The most straightforward anatomical model is that
axonal transsection within active MS lesions causes distal
axonal loss by Wallerian degeneration.
2 Once the axon is
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nected, neuronal death follows a mechanism called dying
back neuropathy. A more complex anatomical model is
required to explain how axonal degeneration passes from
a diseased to a healthy neuron. This is now understood
to be a consequence of retrograde
3,4 and anterograde
trans-synaptic axonal degeneration.
5 Truly, directionality
of the process depends on localization of primary damage
and will in most cases be bidirectional.
6 A physiological
barrier to bidirectional trans-synaptic axonal degeneration
is formed by anatomical structures capable of neuronal
plasticity.
6,7 An important conclusion from these studies
is that the substantial amount of retinal ganglion cell loss
and axonal degeneration following episodes of MS associ-
ated optic neuritis (MSON) masks the more subtle degree
of neurodegeneration attributable to more globally acting
mechanisms.
8,9
An important shortcoming of all optical coherence
tomography (OCT) studies in the literature to date is that
none excluded retinal layer atrophy to be a potential con-
founder of MS lesions in the optic pathways.
4,10 It may be
possible that bidirectional trans-synaptic axonal degenera-
tion does not explain all of the retinal layer atrophy seen
in MS. More global mechanism are also present.
11 There-
fore, to test these hypotheses using structural retinal imag-
ing, one will need to be rigorous about excluding atrophy
data from eyes with MSON and/or lesions within the pos-
terior visual pathways.
But which are the molecular pathways that might lead
to neurodegeneration on a more global level? Current
understanding is that these consist of a cascade of events
eventually leading to neuroaxonal degeneration as sum-
marized in Figure 1. A common feature here is that a
mitochondrial dysfunction is part of every single phase of
this cascade of neurodegeneration.
11–13 As a result of
mitochondrial dysfunction the cellular need for ATP is
partly covered by conversion of pyruvate to lactate. This
change from an aerobic to a nonaerobic metabolism leads
to an increase of lactate levels.
14 Recent translational data
directly relates neuronal loss to a dysfunctional aerobic
energy metabolism.
15 An elegant quantitative method
which permits to reach the cellular level in humans in
vivo is spectral domain OCT.
16
In order to prospectively test the hypothesis that
patients with MS and mitochondrial failure suffer from
more extensive neurodegeneration compared to patients
Figure 1. Prevailing hypotheses on molecular mechanisms leading to a cascade of events leading to more global neurodegeneration in the brain
of patients with multiple sclerosis (MS) as could be expected from bidirectional trans-synaptic axonal degeneration alone. The red ellipse shows
which of these mechanisms have in common, biochemically, that the anaerobic or impaired energy metabolism may cause an increase of systemic
blood lactate levels, a body ﬂuid biomarker. The red box highlights the visual pathway model used in this study using multimodal, structural
imaging biomarkers.
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combined body ﬂuid biomarker and imaging biomarker
approach. Because body ﬂuid biomarker data can only
ever provide indirect correlative evidence, postmortem
immunohistochemical analyses were also performed. We
hypothesized that patients with MS who had higher
serum lactate levels compared to healthy controls will suf-
fer from more extensive atrophy and loss of function.
Methods
Patients
This single centre cohort study was approved by the ethics
committee of the VU University Medical Centre (protocol
number 2010/336) and the scientiﬁc research committee
(protocol number CWO/10-25D). Written, informed con-
sent was obtained from all patients. All donors or their
next of kin provided written informed consent for brain
autopsy, use of material, and clinical information for
research purposes. Inclusion criteria were age above
18 years and a diagnosis of clinically deﬁnite MS accord-
ing to the original McDonald criteria.
17 Exclusion criteria
were pregnancy, a relapse, or a course of steroids in the
last 4 weeks, a diagnosis of HIV or other immunodeﬁ-
ciency, substance abuse in the past 5 years or MRI ﬁnd-
ings that could interfere with evaluation. For healthy
controls additional exclusion criteria were any other neu-
rological or psychiatric disease or a ﬁrst or second degree
relative with a diagnosis of MS. Episodes of MSON were
identiﬁed through patient history and conﬁrmed clinically
using a standard care protocol.
18 The disease course was
classiﬁed into relapsing remitting (RR), secondary progres-
sive (SP) and primary progressive (PP).
19
Clinical scales
Physical disability was recorded on the Expanded Disability
Status Scale score (EDSS), Guy’s Neurological Disability
Scale (GNDS), the Multiple Sclerosis Walking Scale
(MSWS-12) and the 9–hole PEG test (9HPT) measuring
upper limb motor function. For all scales a higher score
indicates more disability. Snellen visual acuities (VA) were
recorded and converted to decimal notation as recom-
mended.
18 Color vision was tested using the Lanthony
desaturated F15–hue test (D-F15d) with a daylight illumina-
tor (6280°K) followed by validated, quantitative analyses.
20
Blood test
Blood samples were taken by antecubital venopuncture
using a standard tourniquet procedure at time of the MRI.
Samples were immediately spun down. Samples were then
alliquoted, coded, and stored in polypropylene tubes at
80°C within 2 h of sampling. Serum samples were avail-
able from 192 of the 263 we have reported on before.
7,21
Serum lactate levels were measured spectrophotometrically
(Agilent 89090A; Agilent Technologies, Santa Clara, CA).
22
The analyst was blinded to all other subject information.
OCT and segmentation
Retinal OCT was performed as previously described.
7,21
In brief all images were obtained with a SD-OCT (Heidel-
berg Spectralis, software version 1.1.6.3, Heidelberg Enge-
neering, Heidelberg, Germany) with the eye tracking
function (EBF) enabled for best accuracy.
23 Data were
collected from a peripapillary ring scan (12°) and a macu-
lar volume scan (20 9 20°).
All scans underwent a rigorous quality control (QC)
check.
24 From a total of 768 scans, 70 scans (9.1%) were
excluded because they failed the validated OSCAR-IB QC
criteria.
24 Automated segmentation was performed with
the manufacturers software (HEYEX version 1.7.1.0, View-
ing Module version 5.7.0.10, Heidelberg Engeneering, Hei-
delberg, Germany). The peripapillary retinal nerve ﬁber
layer (pRNFL), macular RNFL (mRNFL), and macular
ganglion cell complex (mGCC) were taken for analysis.
MRI acquisition
Structural magnetic resonance imaging (MRI) was per-
formed on a 3T whole body system (GE Signa HDxt, Mil-
waukee, WI). The detailed acquisition parameters have
been described previously as well as an example of the 3T
MRI.
7,21 In brief, normalized gray and white matter vol-
umes and lesion volumes were quantiﬁed automatically
using k nearest neighbor classiﬁcation with tissue type
priors (KNN-TTP), and SIENAX (part of the FMRIB
Software Library [FSL] 5.0.4, http://www.fmrib.ox.ac.uk/
fsl). Lesion ﬁlling was applied to minimize the effect of
lesions on atrophy measurements.
Immunohistochemistry
White matter brain samples were obtained from seven
MS patients (average age: 61, 57% male, 57% secondary
progressive multiple sclerosis SPMS, average disease dura-
tion of 37 years) in collaboration with the Netherlands
Brain Bank, Amsterdam, The Netherlands (coordinator
Dr. Huitinga). Cryosections were used for detection of
monocarboxylate transporter 1 (MCT1) (dilution 1:1000,
kindly provided by Dr. Fishbein and Dr. Merezhins-
kaya).
25 Parafﬁn sections were used for detection of lac-
tate dehydrogenase A (LDHA) (dilution 1:3000; Novus
biologicals, Littleton, CO).
26
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All statistical analyses were performed in SAS (version 9.3
SAS Institute Inc., Carry, USA). For statistical analyses the
averaged OCT and D-F15d data of both eyes were used
from each patient. In cases with unilateral MSON, only
data from the nonaffected eye were used. Patients with a
lesion volume of their OR exceeding the highest value
observed in our control cohort were excluded. Controls
were age matched to patients. The cutoff level for high
serum lactate concentrations (2 mmol/L) was taken from
a large reference population of 625 healthy control sub-
jects.
14 Normality was tested graphically and using Shap-
iro–Wilk statistics. Because averaged data were used for
both eye we did not perform generalized estimating equa-
tion (GEE) which corrects for intereye dependencies,
instead data with normal distribution were compared
using the t test. Correlation analyses were performed using
Pearson’s R for normally distributed and Spearman’s R for
non-Gaussian data. The Bonferroni method was used to
correct for multiple correlations. Power calculations were
performed using proc power in SAS with alpha set to 0.05.
Results
Study cohort void of MS lesions in visual
pathways
We identiﬁed 31 patients with MS who did have no clini-
cal or radiological evidence for either MSON or lesions
within their optic radiations. This corresponds to 31/230
(13.5%) of our original cohort.
7 The demographic data of
the patients are summarized in Table 1. The groups were
matched for age, but there were more female patients
compared to healthy control subjects (P<0.01).
The serum lactate levels were signiﬁcantly higher in
patients with MS compared to control subjects (Table 1,
P = 0.029). Importantly, serum lactate levels were not
correlated with either age (P = 0.23), age at onset
(P = 0.42), or disease duration (P = 0.37).
Dominant dyschromatopsia in MS
Color vision was impaired in 20/24 (83.3%) and typical
for an acquired loss of color vision.
20 High contrast VA
averaged at 0.9 with a mode of 1.0 (Table 2). Fourteen
patients had a VA >1.0 and only 3/31 (9.7%) had a VA
<0.8. Color vision was signiﬁcantly more frequently
impaired compared to high contrast VA (v
2 P = 0.01).
Structural relationships
In patients with high serum lactate levels there was signiﬁ-
cantly more retinal layer atrophy of the pRNFL (P = 0.041,
Fig. 2A), mRNFL (P = 0.025, Fig. 2B), and mGCC
(P = 0.041, Fig. 2C) compared to those with normal serum
lactate levels.
There was a trend for more severe cortical thinning in
patients with high compared to normal serum lactate lev-
els, but signiﬁcance was narrowly missed (P = 0.061).
Functional relationships
Patients with high serum lactate levels had signiﬁcantly
more severe impairment of their color vision (confusion
Table 1. Subject characteristics.
Controls MS patients
Subjects 31 31
Gender (m:f) 15:16 5:26
1
Age (years) 53.2 (5.6) 55.1 (10.5)
2
Age at onset n/a 37.6 (8.4)
Disease duration n/a 17.5 (6.3)
EDSS n/a 3.7 (1.7)
Disease course n/a 20 RR, 6 PP, 5 SP
No MSON 31/31 (100%) 21/31 (68%)
3
MSON OD 0/31 (0%) 7/31 (23%)
4
MSON OS 0/31 (0%) 3/31 (10%)
5
Eyes included 62 52
6
Serum lactate 2.39 (0.82) 2.81 (0.89)
7
The mean (SD), n (%) are shown. The disease course is indicated as
RR, relapsing remitting; SP, secondary progressive; PP, primary pro-
gressive. MS, multiple sclerosis; EDSS, Expanded Disability Status Scale
score; MSON, MS associated optic neuritis.
1Signiﬁcantly more female subjects with MS compared to controls
(chi-square test, P = 0.007).
2Statistically no signiﬁcant difference.
3OCT data from both eyes were averaged.
4Only OCT data OS (the nonaffected eye).
5Only OCT data OD (the nonaffected eye).
6OCT data from the 10 eyes with MSON were excluded.
7P = 0.0294.
Table 2. Visual function in MS patients for the pooled cohort and
dichotomized according to serum lactate levels.
MS patients
Pooled
With normal
lactate
With high
lactate
Visual acuity 0.90 (0.10) 0.94 (0.08) 0.91 (0.12)
Confusion index 1.45 (0.42) 1.20 (0.19) 1.54 (0.45)
1
Selectivity index 1.83 (0.46) 1.61 (0.19) 1.90 (0.50)
Confusion angle 51.54 (43.82) 63.49 (5.29) 47.55 (50.22)
Data are shown for high contrast visual acuity and color vision as
mean (SD) or number (%). MS, multiple sclerosis.
1Signiﬁcantly more errors in MS patients with high serum lactate
compared to MS patients with normal serum lactate (P = 0.0096).
ª 2014 The Authors. Annals of Clinical and Translational Neurology published by Wiley Periodicals, Inc on behalf of American Neurological Association. 143
A. Petzold et al. Mitochondrial Failureindex) compared to those with normal serum lactate
levels (Table 2, Fig. 3, P<0.01).
Serum lactate levels were signiﬁcantly correlated with
clinical scales (Fig. 4). The correlation was strongest for
the 9HPT (Pearson R = 0.53, P = 0.002), followed by the
MSWS (Pearson R = 0.50, P = 0.009), EDSS (Spearman’s
R = 0.37, P = 0.041), and GNDS (Pearson R = 0.38,
P = 0.037). Statistical signiﬁcance remained for the 9HPT
and MSWS after correcting for multiple (n = 4) correla-
tions with a corresponding Bonferroni corrected P-value
of (0.0125 = 0.05/4).
Impaired lactate production and transport
in MS lesions
Chronic active MS lesions were characterized by demye-
lination (Fig. 5A) and a rim of activated microglia and
macrophages (Fig. 5B). Immunohistochemical analysis
indicated that the lactate-generating enzyme LDHA was
predominantly expressed by astrocytes throughout the
normal appearing white matter (Fig. 5C). The expression
of LDHA was markedly increased in MS lesions compared
to normal appearing white matter. Interestingly, LDHA
expression localized predominantly to large reactive astro-
cytes (Fig. 5D). Next, the lactate transporter MCT1 was
highly expressed on blood-vessels and astrocyte processes
throughout the normal appearing white matter (Fig. 5E)
and lesions (Fig. 5F).
25
Discussion
This study proposed an in vivo model suitable to test
systemic hypotheses on primary neurodegeneration in
MS. The combination of clinical and MRI data permits to
Figure 2. (A) There was more atrophy of the peripapillary RNFL
(pRNFL) in patients with MS who have high serum lactate levels if
compared to those with normal serum lactate levels. The inset shows
representative images from two patients with MS included. The
location of the peripapillary ring scan OD (commonly used
abbreviation for latin oculus dexter, meaning right eye) is illustrated
by the green circle in the confocal scanning laser ophthalmoscopic
image. The segmented pRNFL is shown as the bright area between
the red and green lines in the OCT image. The averaged pRNFL was
102 lm on the left (serum lactate 1.92 mmol/L) and 72 lm on the
right (serum lactate 2.94 mmol/L). (B) There was more atrophy of the
macular RNFL (mRNFL) in patients with MS who have high serum
lactate levels if compared to those with normal serum lactate levels.
The inset shows representative images from two patients with MS
included. The area of the macular volume scan OD is illustrated by
the green box in the confocal scanning laser ophthalmoscopic image.
The green vertical arrow indicates the location of the OCT scan. The
segmented mRNFL is shown as the bright area between the red and
green lines in the OCT image. The averaged mRNFL was 32.25 lmo n
the left (serum lactate 1.86 mmol/L) and 23.5 lm on the right (serum
lactate 3.61 mmol/L). (C) There was more atrophy of the macular
GCC (mGCC) in patients with MS who have high serum lactate levels
if compared to those with normal serum lactate levels. The inset
shows the same OCT scan OD as in (B) with the segmented mGCC
between the green and blue lines. The averaged mGCC was
105.75 lm on the left and 71.25 lm on the right. The mean and
standard deviation are shown. RNFL, retinal nerve ﬁber layer; MS,
multiple sclerosis; GCC, ganglion cell complex.
144 ª 2014 The Authors. Annals of Clinical and Translational Neurology published by Wiley Periodicals, Inc on behalf of American Neurological Association.
Mitochondrial Failure A. Petzold et al.describe a subgroup of patients with MS in which there is
no MRI evidence for MS lesions within the visual path-
ways. These patients should therefore not suffer from
inner retinal layer atrophy secondary to bidirectional
trans-synaptic axonal degeneration caused by MS lesions
of the visual pathways.
6,7 Consequently, using retinal
OCT as a highly accurate quantitative readout
10,23,27 for
this in vivo model permits to speciﬁcally test for other
mechanisms thought responsible for neurodegeneration in
MS.
11
The main ﬁnding using this novel visual pathway
model was to provide indirect biomarker evidence that
mitochondrial dysfunction was related to neurodegenera-
tion, both structurally and functionally. The biomarker
chosen was lactate because it reﬂects on mitochondrial
dysfunction which is considered a key feature of neurode-
generation in MS (Fig. 1). Consistent with previous data,
serum lactate levels in this study were signiﬁcantly higher
in patients with MS compared to healthy controls.
14,28
Because of the high lipid content of the brain it is inter-
esting noting recent adipous tissue microdialysis data in
MS.
29 Extracellular ﬂuid lactate levels in MS where higher
at baseline and signiﬁcantly increased with exercise if
compared to control levels.
29 Such changes were not
observed for muscle tissue.
29
Structurally, the extent of atrophy in MS patients with
high serum lactate levels exceeded what can be seen by
physiological variation alone.
30,31 However, the need for
OCT QC using validated criteria cannot be overempha-
sized because the observed group differences fall in the
range of known measurement artefacts.
24
Functionally, the signiﬁcant loss of color vision was
associated with higher serum lactate levels. Consistent
with this ﬁnding elevated serum lactate levels were also
related to more extensive loss of function on global scales
(EDSS, GNDS), upper limb function (9HPT), and lower
limb function (MSWS). The scales used have complemen-
tary strength lending more weight to the overall correla-
tive evidence.
A strength of this study was the long disease duration
which might have facilitated demonstrating the structural
and functional relationships with serum lactate in MS.
This advantage was counter balanced by the smaller num-
ber of patients, corresponding to only 15.5% of our origi-
nal cohort.
7,21 This seems inevitable given the high
prevalence of optic pathway involvement in MS.
18 This
may also turn out to be the practical challenge of the pro-
posed model for clinical patient recruitment. Power calcu-
lations on the present data illustrate the actual power of
the present study and how many patients would be
needed for each of the three OCT readouts used
(Table 3). An interesting observation from these power
calculations is that test of function (color vision) per-
forms better than test of structure (OCT). This is interest-
ing because color vision relies on cones which have a
higher metabolic demand compared to rods.
32 In addi-
tion, foveal cone signaling has to pass through an ana-
tomical vulnerable structure, the foveal ﬁbers, also known
as the papillomacular bundle.
33 Finally, acquired loss of
color vision can now be assessed with high accuracy,
using state-of-the art, age adjusted, computerized color
vision tests.
34,35 Such methods will be required for future
longitudinal studies relating quantitative data on color
vision to structural imaging data on integrity of the retina
and visual pathways, genetic and body ﬂuid biomarker
data.
It has long been recognized that the axons constituting
the papillomacular bundle are particularly vulnerable.
36
This might in part be related to their small diameter.
Electron-microscopic studies in primates show a diameter
of around 0.4 lm for the papillomacular bundle with a
complete lack of the larger 2.5 lm ﬁbers seen elsewhere
in the retina.
37 Naturally, there are less mitochondria in
thinner ﬁbers compared to thicker ﬁbers limiting energy
resources by unchanged energy requirements to maintain
axonal conduction.
38 The size-dependent differences in
axonal susceptibility to degeneration have since been cor-
roborated in a human postmortem study using histo-
chemistry.
39 This study demonstrated predominant loss of
the parvocellular layer of the lateral geniculate nucleus
Figure 3. Color vision was more impaired in patients with multiple
sclerosis (MS) who have high serum lactate levels if compared to
those with normal serum lactate levels. A color confusion index of
1.00 indicates a perfect test result from a patient with normal lactate
levels (0.96 mmol/L) and illustrated as inset to the left box. The result
from a patient with impaired color vision (confusion index 2.50) and
high lactate levels (3.44 mmol/L) is shown as inset to the right box.
The blue colored reference cap is indicated as “R”. Dashed lines
indicate directions of confusion typically found for protanomals,
deuteranomals, and tritanomals. The pattern of confusion (closed
lines on the right) are characteristic for an acquired color deﬁcit. The
mean and standard deviation are shown.
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39
Importantly, neurons of the parvocellular pathway are
particularly involved in color vision. In this context, our
ﬁndings indirectly support the clinical observation of a
progressive optic neuropathy in a very small proportion
of patients with MS from the pregenetic and pre-MRI
area.
40,41 Already Parinaud reported slowly progressive
dyschromatopsia in MS.
41 Later, Ashworth reported
nine cases with insidious and progressive visual failure
out of a series of 15 patients with presumed chronic
retrobulbar and chiasmal neuritis. Dyschromatopsia was
not systematically investigated but scotoma to red targets
reported in two cases (#7 & #9).
40
Extending from the visual system to a more global
assessment of the brain, this study narrowly failed to
demonstrate a statistical relationship between serum lac-
tate levels and gray matter atrophy (P = 0.06). A limita-
tion here is the sample size as further illustrated by the
power calculations (Table 3). A possible explanation
might be that the spatial resolution of MRI is lower com-
Figure 4. Serum lactate levels correlated with the (A) EDSS (R = 0.37, P = 0.041), (B) GNDS (R = 0.38, P = 0.037), (C) MSWS (R = 0.50,
P = 0.009) and (D) 9–hole PEG test (R = 0.53, P = 0.002). EDSS, Expanded Disability Status Scale score; GNDS, Guy’s Neurological Disability Scale;
MSWS-12, Multiple Sclerosis Walking Scale.
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macrophages (B). LDHA staining intensity is increased in MS lesions (D) compared to normal appearing white matter (C). MCT1 is highly
expressed on blood-vessels in both normal appearing white matter (E) and lesions (F). MS, multiple sclerosis; LDHA, lactate dehydrogenase A;
MCT, monocarboxylate transporter 1.
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ter remains technically difﬁcult.
42 For both reasons MRI
data may be more noisy compared to OCT data in this
particular context.
Next, we studied the cellular distribution of the lactate
generating enzyme LDHA and monocarboxylate trans-
porter-1 (MCT-1), which is the main lactate transporter
in well-characterized MS brain tissue samples. The data
suggest that enhanced levels of the lactate-producing
enzyme LDHA in combination with marked endothelial
lactate transporters in MS lesions might contribute to
increased lactate levels. Future studies aimed to investigate
the link of the present biomarker data with pathological
studies of the eye and anterior visual pathways will need
to consider cell type speciﬁc metabolic pathways as well
as relevant transporters.
25 Such future studies should also
consider adipous tissue as a likely source for systemic lac-
tate levels based on microdialysis data.
29
There are other limitations of this study which need to
be discussed. Anatomically there is large variability of the
retinal axonal projections through the optic radiations
with relevant right left asymmetry.
43 Despite state of the
art MRI tractrography currently used in the ﬁeld,
4 not all
retino-cortical projections will be captured. MR spectros-
copy and quantitative MRI metrics will be required to
investigate more diffuse pathology.
44,45 Next, it is not clear
if all radiological white matter lesions are relevant. Radio-
logical signal changes of the white matter increase with age
and were clearly seen in the present healthy control group.
The chosen pragmatic approach to use a quantitative cut-
off for the white matter lesion volume based on the control
group might need qualitative reﬁnements. Our 3T MRI
protocol is very sensitive for detection of MS lesions, how-
ever, ultrahighﬁeld MR might be even better suited to sep-
arate MS plaques from other white matter signal
changes.
4,44,46 Certainly, much more data will be required
on visual function, including testing for low contrast sensi-
tivity, dyschromatopsia and electrophysiology.
34,35,47,48
The full spectrum of psychophysiological testing has not
yet been exploited, possibly dynamic visual tests are a step
in this direction, suitable for quantitative, longitudinal
readouts.
49 Finally lactate can be elevated for a number of
reasons we have discussed in detail.
14 In the current cohort
there was no clinical evidence to suggest an inclusion bias
to the high lactate group due to systemic infection, muscle
atrophy, or deconditioning.
A limitation of the study design was that we were
unable to say whether the here observed subtle impair-
ment of mitochondrial function might already play a role
in patients with clinically isolated syndromes. The litera-
ture suggests that if lesions to the visual pathways are
excluded, no pRNFL atrophy was observed in clinical iso-
lated syndromes.
50,51 There is rather conﬂicting data on
macular volume on a group level and conﬁrmation of
these data in a longitudinal study, excluding lesions in
the visual pathways, is awaited.
50,52,52,53
In conclusion, this study describes a visual pathway
model suitable to test systemic and genetic hypotheses on
pathways of neurodegeneration in MS.
11 The biomarker
data suggests that there are structural and functional rela-
tionship of mitochondrial dysfunction and primary neu-
rodegeneration in long-standing MS. There is a need for
neuroproctive studies aimed to improve mitochondrial
function, but results have been conﬂicting so far.
1 The
sample size calculations on the here described visual path-
way model, void of MS lesions, suggest that future studies
to clarify these burning issues are feasible.
Acknowledgment
The MS Center VUMC is partially funded by a program
grant of the Dutch MS Research Foundation (grant 09-358d
MS). This work has partly been funded by the Catholic Uni-
versity of Rome and the University of Catania. Shipment of
samples has been privately sponsored by A. P. The authors’
work described in this paper is supported by the University
College London Comprehensive Biomedical Research
Centre andthe MoorﬁeldsBiomedical Research Centre.
Conﬂict of Interest
Dr. Petzold reports personal fees from Novartis, not related
to the submitted work. Dr. Wattjes reports personal fees
from Biogen Idec, outside the submitted work.
References
1. Maghzi A-H, Minagar A, Waubant E. Neuroprotection in
multiple sclerosis: a therapeutic approach. CNS Drugs
2013;27:799–815.
2. Trapp B, Peterson J, Ransohoff RM, et al. Axonal
transection in the lesions of multiple sclerosis. N Engl J
Med 1998;338:278–285.
Table 3. Sample sizes required to test systemic hypotheses of
neurodegeneration on the suggested optic pathway model using
structural (OCT) and functional (color vision) readouts.
Readout Actual power Desired power Numbers needed
OCT pRNFL 41% 80% n = 72
OCT mRNFL 43% 80% n = 72
OCT mGCC 41% 80% n = 68
MRI GM
(Grey matter)
33% 80% n = 74
Color vision 67% 80% n = 36
Power calculations were based on a = 0.05 for a two-sample t Test.
pRNFL, peripapillary retinal nerve ﬁber layer; mRNFL, macular RNFL;
mGCC, macular ganglion cell complex.
148 ª 2014 The Authors. Annals of Clinical and Translational Neurology published by Wiley Periodicals, Inc on behalf of American Neurological Association.
Mitochondrial Failure A. Petzold et al.3. Jindahra P, Petrie A, Plant GT. Retrograde trans-synaptic
retinal ganglion cell loss identiﬁed by optical coherence
tomography. Brain 2009;132:628–634.
4. Klistorner A, Sriram P, Vootakuru N, et al. Axonal loss of
retinal neurons in multiple sclerosis associated with optic
radiation lesions. Neurology 2014;82:2165–2172.
5. Gabilondo I, Mart  ınez-Lapiscina EH, Mart  ınez-Heras E,
et al. Trans-synaptic axonal degeneration in the visual
pathway in multiple sclerosis. Ann Neurol 2014;75:98–107.
6. Balk LJ, Steenwijk MD, Tewarie P, et al. Bidirectional
trans-synaptic axonal degeneration in the visual pathway in
multiple sclerosis. J Neurol Neurosurg Psychiatry 2014;
[Epub ahead of print].
7. Balk LJ, Twisk JWR, Steenwijk MD, et al. A dam for
retrograde axonal degeneration in multiple sclerosis?
J Neurol Neurosurg Psychiatry 2014;85:782–789.
8. Costello FE, Klistorner A, Kardon R. Optical coherence
tomography in the diagnosis and management of optic
neuritis and multiple sclerosis. Ophthalmic Surg Lasers
Imaging 2011;42(suppl):S28–S40.
9. Zimmermann H, Freing A, Kaufhold F, et al. Optic
neuritis interferes with optical coherence tomography and
magnetic resonance imaging correlations. Mult Scler
2013;19:443–450.
10. Petzold A, de Boer JF, Schippling S, et al. Optical
coherence tomography in multiple sclerosis: a
systematic review and meta-analysis. Lancet Neurol
2010;9:921–932.
11. Friese MA, Schattling B, Fugger L. Mechanisms of
neurodegeneration and axonal dysfunction in multiple
sclerosis. Nat Rev Neurol 2014;10:225–238.
12. Lassmann H, van Horssen J, Mahad D. Progressive
multiple sclerosis: pathology and pathogenesis. Nat Rev
Neurol 2012;8:647–656.
13. Witte ME, Mahad DJ, Lassmann H, van Horssen J.
Mitochondrial dysfunction contributes to
neurodegeneration in multiple sclerosis. Trends Mol Med
2014;20:179–187.
14. Amorini AM, Nociti V, Petzold A, et al. Serum lactate as a
novel potential biomarker in multiple sclerosis. Biochim
Biophys Acta 2014;1842:1137–1143.
15. Choi J, Chandrasekaran K, Demarest TG, et al. Brain
diabetic neurodegeneration segregates with low intrinsic
aerobic capacity. Ann Clin Transl Neurol 2014;1:589–604.
16. Costello FE. Optical coherence tomography technologies:
which machine do you want to own? J Neuroophthalmol
2014;34(suppl):S3–S9.
17. McDonald W, Compston A, Edan G, et al. Recommended
diagnostic criteria for multiple sclerosis: guidelines from
the International Panel on the diagnosis of multiple
sclerosis. Ann Neurol 2001;50:121–127.
18. Petzold A, Wattjes MP, Costello F, et al. The investigation
of acute optic neuritis: a review and proposed protocol.
Nat Rev Neurol 2014;10:447–458.
19. Lublin F, Reingold S. Deﬁning the clinical course of
multiple sclerosis: results of an international survey.
National Multiple Sclerosis Society (USA) Advisory
Committee on Clinical Trials of New Agents in Multiple
Sclerosis. Neurology 1996;46:907–911.
20. Vingrys AJ, King-Smith PE. A quantitative scoring
technique for panel tests of color vision. Invest
Ophthalmol Vis Sci 1988;29:50–63.
21. Balk L, Tewarie P, Killestein J, et al. Disease course
heterogeneity and OCT in multiple sclerosis. Mult Scler
2014;20:1198–1206.
22. Artiss JD, Karcher RE, Cavanagh KT, et al. A liquid-stable
reagent for lactic acid levels. Application to the Hitachi
911 and Beckman CX7. Am J Clin Pathol 2000;114:139–
143.
23. Balk LJ, Petzold A. Inﬂuence of the eye-tracking-based
follow-up function in retinal nerve ﬁber layer thickness
using Fourier-domain optical coherence tomography.
Invest Ophthalmol Vis Sci 2013;54:3045.
24. Schippling S, Balk L, Costello F, et al. Quality control for
retinal OCT in multiple sclerosis: validation of the OSCAR-
IB criteria. Mult Scler 2014; [Epub ahead of print].
25. Nijland PG, Michailidou I, Witte ME, et al. Cellular
distribution of glucose and monocarboxylate transporters
in human brain white matter and multiple sclerosis
lesions. Glia 2014;62:1125–1141.
26. Witte ME, Nijland PG, Drexhage JAR, et al. Reduced
expression of PGC-1a partly underlies mitochondrial
changes and correlates with neuronal loss in multiple
sclerosis cortex. Acta Neuropathol 2013;125:231–243.
27. Balk LJ, Petzold A. Current and future potential of retinal
optical coherence tomography in multiple sclerosis with
and without optic neuritis. Neurodegener Dis Manag
2014;4:165–176.
28. Hansen D, Wens I, Keytsman C, et al. Is long-term
exercise intervention effective to improve cardiac
autonomic control during exercise in subjects with
multiple sclerosis? A randomized controlled trial. Eur J
Phys Rehabil Med 2014 [Epub ahead of print].
29. M€ ahler A, Steiniger J, Bock M, et al. Is metabolic
ﬂexibility altered in multiple sclerosis patients? PLoS One
2012;7:e43675.
30. Balk LJ, Sonder JM, Strijbis EMM, et al. The physiological
variation of the retinal nerve ﬁber layer thickness and
macular volume in humans as assessed by spectral
domain-optical coherence tomography. Invest Ophthalmol
Vis Sci 2012;53:1251–1257.
31. Balk L, Mayer M, Uitdehaag B, Petzold A. Physiological
variation of segmented OCT retinal layer thicknesses is
short-lasting. J Neurol 2013;260:3109–3114.
32. Perkins GA, Ellisman MH, Fox DA. Three-dimensional
analysis of mouse rod and cone mitochondrial cristae
architecture: bioenergetic and functional implications. Mol
Vis 2003;9:60–73.
ª 2014 The Authors. Annals of Clinical and Translational Neurology published by Wiley Periodicals, Inc on behalf of American Neurological Association. 149
A. Petzold et al. Mitochondrial Failure33. Plant GT, Perry VH. The anatomical basis of the
caecocentral scotoma. New observations and a review.
Brain 1990;113(Pt 5):1441–1457.
34. Rodriguez-Carmona M, O’Neill-Biba M, Barbur JL.
Assessing the severity of color vision loss with implications
for aviation and other occupational environments. Aviat
Space Environ Med 2012;83:19–29.
35. Barbur JL, Konstantakopoulou E. Changes in color vision
with decreasing light level: separating the effects of normal
aging from disease. J Opt Soc Am A Opt Image Sci Vis
2012;29:A27–A35.
36. Uhthoff W. Untersuchungen € uber den Einﬂuss des
chronischen Alkoholismus auf das menschliche Sehorgan.
Arch Ophthalmol 1886;32:95–188.
37. Ogden TE. Nerve ﬁber layer of the primate retina:
morphometric analysis. Invest Ophthalmol Vis Sci
1984;25:19–29.
38. Sadun AA, La Morgia C, Carelli V. Mitochondrial optic
neuropathies: our travels from bench to bedside and
back again. Clin Experiment Ophthalmol 2013;41:
702–712.
39. Evangelou N, Konz D, Esiri MM, et al. Size-selective
neuronal changes in the anterior optic pathways suggest a
differential susceptibility to injury in multiple sclerosis.
Brain 2001;124:1813–1820.
40. Ashworth B. Chronic retrobulbar and chiasmal neuritis. Br
J Ophthalmol 1967;51:698.
41. Parinaud H. Troubles oculaires de la scl  erose en plaques.
Prog M  ed (Paris) 1884;12:641–650.
42. Chard DT, Parker GJM, Grifﬁn CMB, et al. The
reproducibility and sensitivity of brain tissue volume
measurements derived from an SPM-based segmentation
methodology. J Magn Reson Imaging 2002;15:259–267.
43. Jeelani NUO, Jindahra P, Tamber MS, et al.
‘Hemispherical asymmetry in the Meyer’s Loop’: a
prospective study of visual-ﬁeld deﬁcits in 105 cases
undergoing anterior temporal lobe resection for epilepsy.
J Neurol Neurosurg Psychiatry 2010;81:985–991.
44. Wattjes MP, Harzheim M, Lutterbey GG, et al. High ﬁeld
MR imaging and 1H-MR spectroscopy in clinically isolated
syndromes suggestive of multiple sclerosis: correlation
between metabolic alterations and diagnostic MR imaging
criteria. J Neurol 2008;255:56–63.
45. Pfueller CF, Brandt AU, Schubert F, et al. Metabolic
changes in the visual cortex are linked to retinal nerve
ﬁber layer thinning in multiple sclerosis. PLoS One 2011;6:
e18019.
46. Sinnecker T, Oberwahrenbrock T, Metz I, et al. Optic
radiation damage in multiple sclerosis is associated with
visual dysfunction and retinal thinning – an ultrahigh-ﬁeld
MR pilot study. Eur Radiol 2014;25:122–131.
47. Balcer LJ, Baier ML, Cohen JA, et al. Contrast letter acuity
as a visual component for the Multiple Sclerosis
Functional Composite. Neurology 2003;61:1367–1373.
48. Schnurman ZS, Frohman TC, Beh SC, et al. Retinal
architecture and mfERG: optic nerve head component
response characteristics in MS. Neurology 2014;82:1888–
1896.
49. Raz N, Hallak M, Ben-Hur T, Levin N. Dynamic visual
tests to identify and quantify visual damage and repair
following demyelination in optic neuritis patients. J Vis
Exp 2014;(86). doi: 10.3791/51107.
50. Outteryck O, Zephir H, Defoort S, et al. Optical coherence
tomography in clinically isolated syndrome: no evidence of
subclinical retinal axonal loss. Arch Neurol 2009;66:1373–
1377.
51. Oberwahrenbrock T, Ringelstein M, Jentschke S, et al.
Retinal ganglion cell and inner plexiform layer thinning in
clinically isolated syndrome. Mult Scler 2013;19:1887–1895.
52. Saidha S, Syc SB, Ibrahim MA, et al. Primary retinal
pathology in multiple sclerosis as detected by optical
coherence tomography. Brain 2011;134:518–533.
53. Khanifar AA, Parlitsis GJ, Ehrlich JR, et al. Retinal nerve
ﬁber layer evaluation in multiple sclerosis with spectral
domain optical coherence tomography. Clin Ophthalmol
2010;4:1007–1013.
150 ª 2014 The Authors. Annals of Clinical and Translational Neurology published by Wiley Periodicals, Inc on behalf of American Neurological Association.
Mitochondrial Failure A. Petzold et al.